December 12, 2017
There’s no question that MIGS has become a worthwhile add-on to cataract surgery. The well-deserved amount of attention in journals and at meetings to these new procedures is impressive. Still, it’s surprising that only about 16% of U.S. surgeons are using these devices and techniques, per several industry sources.
Every cataract surgeon should get involved with these techniques and devices. As many as 25% of cataract patients can benefit from MIGS because of coexisting glaucoma or ocular hypertension. The procedures are intuitive and do not dramatically lengthen the time of surgery. They are FDA-approved and reimbursed fairly. To not do MIGS, subjecting patients to a lifetime of taking drops, is just missing a great opportunity.